Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease – The Union of Two Culprits

Saad Emhmed Ali¹, Mindie H. Nguyen¹,²

¹Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, United States of America
²Department of Epidemiology and Population Health, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, United States of America

Correspondence:
Mindie H. Nguyen, M.D., M.A.S.
Professor of Medicine (Gastroenterology and Hepatology, Liver Transplant) and by courtesy of Epidemiology and Population Health
Stanford University Medical Center
Email: mindiehn@stanford.edu
Abstract:

Non-alcoholic fatty liver disease (NAFLD) continues to rise and has become the most common cause of chronic liver disease among all ages and ethnicities. Metabolic disorders such as obesity and insulin resistance are closely associated with sarcopenia and NAFLD. Sarcopenic obesity is a clinical disorder characterized by the simultaneous loss of skeletal muscle and gain of adipose tissue. It is associated with worse outcomes in individuals with NAFLD. It is projected that NAFLD and sarcopenia will rise as the prevalence of obesity continues to increase at an unparallel rate. Recently, sarcopenia and sarcopenic obesity have gained considerable interest, but we still lack a well-defined definition and a management approach. Therefore, it is imperative to continue shining the light on this topic and better understand the underlying mechanism as well as treatment options. In this review article, we aimed to address the pathophysiology, impact, and outcomes of sarcopenic obesity on NAFLD.

Key words: Sarcopenia; Non-alcoholic Fatty Liver Disease; Obesity, Insulin Resistance; Prevalence; Metabolic Diseases
Introduction:

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease with a reported global prevalence of 25%, with regional variation of about 30% for the United States, South America, the Middle East, 24% for Europe, and 14% for Africa [1–3]. NAFLD includes a clinicopathologic continuum, from an excess of hepatic steatosis to non-alcoholic steatohepatitis (NASH), progressive fibrosis, cirrhosis, liver cancer, end-stage liver disease requiring liver transplantation, and death [4–6]. NAFLD is commonly noticed in obese but also in nonobese individuals with metabolic derangement such as visceral obesity and insulin resistance, both of which closely implicated in sarcopenia "muscle wasting" [7–9].

Sarcopenia is identified as a progressive and diffuse decline of skeletal muscle mass, function, and strength [10]. Insulin resistance, vitamin D deficiency, and chronic systemic inflammation are common pathogenetic pathways for both sarcopenia and NAFLD [11,12]. Sarcopenic obesity is a term used to describe the coexistence of sarcopenia and obesity [13,14]. Sarcopenia and sarcopenic obesity were first observed to be entangled in NAFLD in the Korean Sarcopenic Obesity study by Hong et al., who found that people with higher body mass index [BMI] and fat mass had an increased prevalence of NAFLD [15]. Since then, this observation has gained significant interest, and sarcopenic obesity has been found to be associated with a higher risk of metabolic syndrome, cardiovascular disease, liver disease, frailty, mobility disability, healthcare expenses, and mortality in the ambulatory population [16,17]. Among inpatients with end-stage liver disease waiting for liver transplantation, the prevalence of sarcopenic obesity can be up to 35% [18]. In this current review, we aim to present an up to date overview of the definitions,
diagnostic methods, pathophysiology, impacts, and management approaches for sarcopenic obesity for individuals with NAFLD.

**Definitions and diagnostic modalities:**

Sarcopenia was first termed in 1989 by Rosenberg et al. as a muscle loss in the aging population [19]. Although several definitions coexist, sarcopenia's well-adopted description is an age-related process characterized by progressive loss of skeletal muscle mass and function [10]. Several assessment tools can be utilized to assess muscle mass and function (Table 1). To determine the muscle mass, anthropometric measurements such as the thickness of the skin fold, mid-upper arm muscle circumference (MAMC), and calf circumference have been tried in the past and found to be inaccurate; therefore, these methods are not recommended [20]. Imaging such as computed tomography (CT) at the level of the third lumbar vertebra to assess skeletal muscle index (SMI) (cut-off value of <50 cm$^2$/m$^2$ in men and <39 cm$^2$/m$^2$ in women) and magnetic resonance imaging (MRI) have been used effectively to differentiate between muscle, fat and other soft tissues. However, due to risk of radiation and/or cost, these tests have not been widely used in routine clinical practice [20–22] (Figure 1). Instead, dual-energy X-ray absorptiometry (DEXA) is generally recognized as the gold assessment tool to assess the muscle mass in most cases, due to its low cost, low radiation risk of radiation, and reasonable accuracy [23]. Bioimpedance analysis (BIA) can be also used as an affordable alternative method to DEXA [23]. Lastly and importantly, it should be noted that the accuracy of both BIA and DEXA in measuring muscle mass requires patients to be well hydrated prior to undergoing these tests.
In regards to muscle function assessment, there are several proposed methods, but the most common practice is to measure hand-grip strength [24]. The short physical performance battery (SPPB), gait speed, timed get-up-and-go test are other tests to measure the physical performance of muscle [20,25].

The definition of obesity should also be revisited for a number of reasons. While obesity is generally known as a condition of excessive fat deposition and routinely evaluated in clinical practice using body mass index (BMI), waist circumference, and DEXA, there are limitations to these techniques. First, BMI does not differentiate between fat or lean body mass. Similarly, BMI does not differentiate between “dry” euvolemic weight and “wet” hypervolemic individuals such as those with ESLD. In addition, the diagnostic cut-off for obesity adults is race/ethnic dependent [26]. Obesity and overweight are defined as BMI > 30 and 25 kg /m² in non-Asians and > 27.5 and 23.0 kg/m² in Asians, respectively, as complications of obesity occur at a lower BMI in Asians [26]. Additional education efforts may be needed to raise the awareness of these racial/ethnic variation since a recent U.S. population-based study reported the highest rate of discordance between self-perception of overweight and actual weight among Asians with NAFLD [27].

Finally, sarcopenic obesity describes a combination of skeletal muscle loss and fat gain, initially observed by Baumgartner et al.; and this condition is commonly found in an elderly population [28]. With aging, muscle mass decreases and adipose tissue increases; and by the third decade of life, muscle mass decreases by about 1% per year [28,29]. Sarcopenic obesity has been shown to associate with higher morbidity and mortality than either obesity or sarcopenia alone.
Comorbidities that have been described to associate with sarcopenic obesity include metabolic syndrome, insulin resistance, hypertension, and cardiovascular disease \(^{30,31}\).

**Epidemiology, prevalence, and risk factors**

As the body composition of fat and muscle change with aging, there are expected physiologic changes with age. Body fat increases with age and peaks in the seventh decade of life and then declines \(^{32,33}\). On the other hand, muscle mass decreases with age starting in the fourth decade \(^{34}\). In the cases of pathologic muscle loss and pathologic fat accumulation, there are no well-defined cut-off values, which consequently give rise to wide variation in the reported prevalence of this condition \(^{25,28,31,35–40}\). The prevalence values range from 2% to 25% in studies used bioelectrical impedance analysis (BIA) and anthropometric measurements \(^{41–43}\). In studies using DEXA, the reported prevalence was higher with values ranging from 2.7% to 84% \(^{25,28,38,40,44–48}\).

In a recent analysis of 270 individuals aged 65 years or older who were enrolled in the Frailty in Brazilian Older People Study, the prevalence of sarcopenic obesity was 29.3% with sarcopenic obesity diagnosed via DEXA and defined as a body fat percentage ≥ 38% or ≥ 27% and appendicular skeletal muscle mass index (ASMMI) of < 5.45 kg/m² or < 7.26 kg/m² in men or women, respectively \(^{49}\).

The risk factors for sarcopenic obesity include age-related decrease in the resting metabolic rate due to low physical activity, decreased mitochondrial volume and its oxidative capacity \(^{50–53}\). Sex-related hormonal changes in estrogen, progesterone and testosterone also affect the muscle and fat composition. For example, in post-menopausal women, the body fat, in particular the visceral fat, increases and the muscle mass decreases as a result of low estrogen levels \(^{54}\). In men,
testosterone stimulates muscle regeneration, and its deficiency which decrease by about 1% each year can promote low muscle mass and high fat mass \[^{55,56}\]. Other risk factors are sedentarism, ethnicity with higher sarcopenic obesity prevalence in Hispanic and non-Hispanic whites compared to non-Hispanic blacks \[^{48,57}\]. Finally, sarcopenic obesity was also found to be highly prevalent in patients with advanced chronic kidney disease (CKD) such as CKD stage 4 \[^{58}\].

**The pathogenesis of sarcopenic obesity and NAFLD**

Several pathophysiological mechanisms such as insulin resistance, high pro-inflammatory cytokines, decreased exercise, and hormonal changes have been described as common pathways for both NAFLD and sarcopenic obesity \[^{59}\]. The muscle-liver-adipose tissue axis's autocrine-pathways have been suggested as a leading cause of NAFLD and sarcopenic obesity as shown in Figure 2 \[^{60–62}\], though the exact interplay between skeletal muscle, liver, and adipose tissue is still not yet fully understood. Adipose tissue has been recognized as an endocrine organ that secrets hormones called adiponectin and leptin, both of which play a vital role in regulating insulin sensitivity, glucose, and lipid metabolism \[^{60,63}\]. First, adiponectin enhances insulin sensitivity and has antifibrotic, anti-inflammatory, and antisteatotic effects on the liver \[^{63,64}\]. Therefore, reduction in the adiponectin level leads to insulin resistance and glucose intolerance and may lead to hepatic injury and fatty liver \[^{63,64}\]. Second, leptin stimulates hepatic stellate cells, which in turn enhance the process of fibrogenesis and inflammation in the liver \[^{60,65}\]. Once the hepatic stellate cell is activated, it can also produce more leptin and further strengthen the fibrogenesis cascade, eventually leading to more liver fibrosis and cirrhosis \[^{60,65}\]. Furthermore, leptin promotes the progression of liver fibrosis by stimulating the synthesis of transforming growth factor beta (TGFβ) in the Kupffer cells \[^{60}\].
Skeletal muscles also act as endocrine organ via the autocrine-pathways and secrete important myokines [66]. One of these myokines is called myostatin, a TGFβ superfamily member, an essential regulator of the skeletal muscles, adipose tissue, and liver metabolisms [66]. Myostatin has a lipogenesis effect that increases adipose tissue mass and lowers adiponectin secretion. In addition, myostatin has a proteostasis effect that decreases the skeletal muscle mass [60,66]. In animal model studies, blocking the function of myostatin has been shown to lower insulin resistance, enhance skeletal muscle mass, and protect against the development of fatty liver [67,68]. The trigger for this muscle-liver-adipose tissue interplay was speculated to begin in the skeletal muscle with downstream influence on both adipose tissue and the liver [60].

The other important myokine is interleukin 6 (IL-6), which plays a potential role in regulating fatty acid oxidation in the liver and insulin resistance [60].

**Sarcopenic obesity impact in non-alcoholic fatty liver disease**

Sarcopenia and obesity are associated with a higher risk of cardiovascular and metabolic diseases and higher healthcare-related expenditure and mortality in the elderly population [16,17,69]. Obesity is associated with higher level of liver fibrosis and worse prognosis in patients with NASH [70], and sarcopenia was found to be one of the culprits contributing to the progression of NAFLD-associated fibrosis [71]. In a study of 225 patients with histologically proven NASH by Petta et al., the presence of sarcopenia was associated with more severe fibrosis [62]. Another study by Lee et al. revealed a strong association between sarcopenia and advanced hepatic fibrosis in NAFLD patients that was independent of the other co-factors such as insulin resistance and obesity [9]. In another study of 309 patients with biopsy-proven NAFLD by Koo et al., sarcopenic patients had a
higher likelihood of developing NASH than non-sarcopenic patients (odds ratio 2.28; 95% confidence interval 1.21–4.30) [8]. The risk of all-cause mortality was also shown to be increased by 24% in sarcopenic obese individuals compared with those without sarcopenic obesity in a large meta-analysis by Tian et al. [17]. The negative impact of sarcopenic obesity was not only limited to people with NAFLD but also in patients with cancers who were found to have higher risk of complications related to treatments, poor physical performance and shorter survival if sarcopenic obesity was present [72].

**Conclusion**

Sarcopenic obesity is a co-occurrence of two significant comorbidities with a higher risk of morbidity and mortality than either obesity or sarcopenia alone. It is a relatively new concept that is increasingly recognized to occur in a significant proportion of the population and associate with poor outcomes, especially in the elderly population and those with NAFLD. There is a vicious cycle in which sarcopenic obesity and NAFLD contribute to each other through the complex interplay of the muscle-adipose tissue-liver axis. A clear consensus on the definition of sarcopenic obesity is needed to encourage more timely diagnosis, to better inform clinical management, and to facilitate future research.
**Table 1.** Commonly used tests to assess sarcopenia (muscle mass & function)

| Muscle mass                                           | Muscle function                                      |
|--------------------------------------------------------|------------------------------------------------------|
| L-3 Computed tomography (CT) (skeletal muscle index)   | Handgrip strength (HGS)                              |
| Magnetic resonance imaging (MRI)                       | Short physical performance battery (SPPB)           |
| Dual-energy X-ray absorptiometry (DEXA)                | Gait speed                                           |
| Bioimpedance analysis (BIA)                            | Timed get-up-and-go test                             |
Figure 1. Computed tomography (CT) images at the third lumbar vertebra comparing two patients with cirrhosis and same body mass index but one has sarcopenia and other is not. Left image shows sarcopenia with L3mi of 49.82 cm²/m². Right image shows non-sarcopenia with L3mi of 70.8 cm²/m². These abdominal CT images were utilized by Montano-Loza et al. in 2012 and cutoff-values offered by Baumgartner et al. in 1998. Red color denotes abdominal wall muscle, psoas and paraspinal muscles. (Use with permission from Elsevier)
Figure 2. Muscle-liver-adipose tissue axis autocrine interplay that leads to sarcopenic obesity and fatty liver. IL-6: Interleukin-6.
Author Contributions:
The Conceptualization, Saad Emhmed Ali and Mindie Nguyen.; methodology, Saad Emhmed Ali and Mindie Nguyen.; writing—original draft preparation, Saad Emhmed Ali.; writing—review and editing, Mindie Nguyen.; visualization, Mindie Nguyen.; supervision, Mindie Nguyen. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We thank Elsevier for the permission to use a figure from Montano-Loza et al. (Reference # 22, Order # 4978930844585)

Conflicts of Interest:
Saad Emhmed Ali: None to disclose
Mindie Nguyen: Research funding: Pfizer, Enanta, Gilead Sciences. Consultation/advisory board: Intercept, Gilead.
References

1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. Published online 2018. doi:10.1038/nrgastro.2017.109

2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. Published online 2016. doi:10.1002/hep.28431

3. Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. *Liver Int*. Published online 2019. doi:10.1111/liv.14038

4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. Published online 2018. doi:10.1002/hep.29367

5. Le MH, Devaki P, Ha NB, et al. Prevalence of non-Alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. *PLoS One*. Published online 2017. doi:10.1371/journal.pone.0173499

6. Kim D, Li AA, Perumpail BJ, et al. Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. *Hepatology*. Published online 2019. doi:10.1002/hep.30161

7. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. *J Intern Med*. Published online 2020. doi:10.1111/joim.13069

8. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. *J Hepatol*. Published online 2017. doi:10.1016/j.jhep.2016.08.019

9. Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). *Hepatology*. Published online 2016. doi:10.1002/hep.28376

10. Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr*. Published online 2017. doi:10.1016/j.clnu.2016.09.004

11. Janssen I. Influence of sarcopenia on the development of physical disability: The cardiovascular health study. *J Am Geriatr Soc*. Published online 2006. doi:10.1111/j.1532-5415.2005.00540.x

12. Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: Sarcopenia in cirrhosis - Aetiology, implications and potential therapeutic interventions. *Aliment Pharmacol Ther*. Published online 2016. doi:10.1111/apt.13549

13. Choi KM. Sarcopenia and sarcopenic obesity. *Korean J Intern Med*. Published online 2016. doi:10.3904/kjim.2016.193

14. Waters DL, Baumgartner RN. Sarcopenia and Obesity. *Clin Geriatr Med*. Published online 2011. doi:10.1016/j.cger.2011.03.007

15. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic...
fatty liver disease: The Korean Sarcopenic Obesity Study. *Hepatology*. Published online 2014. doi:10.1002/hep.26716

16. Kim TN, Choi KM. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. *J Cell Biochem*. Published online 2015. doi:10.1002/jcb.25077

17. Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. *Geriatr Gerontol Int*. Published online 2016. doi:10.1111/ggi.12579

18. Carias S, Castellanos AL, Vilchez V, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. *J Gastroenterol Hepatol*. Published online 2016. doi:10.1111/jgh.13166

19. Rosenberg IH. Summary comments. *Am J Clin Nutr*. Published online 1989. doi:10.1093/ajcn/50.5.1231

20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. Published online 2010. doi:10.1093/ageing/afq034

21. Carey EJ, Lai JC, Sonnenday C, et al. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. *Hepatology*. Published online 2019. doi:10.1002/hep.30828

22. Montano-Loza AJ, Meza-Junco J, Prado CMM, et al. Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis. *Clin Gastroenterol Hepatol*. Published online 2012. doi:10.1016/j.cgh.2011.08.028

23. Edwards MH, Buehring B. Novel Approaches to the Diagnosis of Sarcopenia. *J Clin Densitom*. Published online 2015. doi:10.1016/j.jocd.2015.04.010

24. Trosclair D, Bellar D, Judge LW, Smith J, Mazeron N, Brignac A. Hand-Grip Strength as a Predictor of Muscular Strength and Endurance. *J Strength Cond Res*. Published online 2011. doi:10.1097/jsc.0b013e3182425576

25. Meng P, Hu YX, Fan L, et al. Sarcopenia and sarcopenic obesity among men aged 80 years and older in Beijing: Prevalence and its association with functional performance. *Geriatr Gerontol Int*. Published online 2014. doi:10.1111/ggi.12211

26. Erratum: WHO expert consultation. Appropriate body-mass index in Asian populations and its implications for policy and intervention strategies (Lancet (January 10, 2004) 363 (157-163)). *Lancet*. Published online 2004.

27. Nguyen VH, Yeo YH, Zou B, et al. Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD. *J Intern Med*. Published online 2020:1-11. doi:10.1111/joim.13203

28. Baumgartner RN. Body composition in healthy aging. In: *Annals of the New York Academy of Sciences*. ; 2000. doi:10.1111/j.1749-6632.2000.tb06498.x

29. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. *Front Physiol*. Published online 2012. doi:10.3389/fphys.2012.00260

30. Van Aller C, Lara J, Stephan BCM, et al. Sarcopenic obesity and overall mortality: Results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999–2004. *Clin Nutr*. Published online 2019. doi:10.1016/j.clnu.2018.01.022

31. Gusmão-Sena MHL, Curvello-Silva K, Barreto-Medeiros JM, Da-Cunha-Daltro CH. Association between sarcopenic obesity and cardiovascular risk: Where are we? *Nutr Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 31 December 2020 doi:10.20944/preprints202012.0822.v1*
32. Flegal KM, Shepherd JA, Looker AC, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. *Am J Clin Nutr.* Published online 2009. doi:10.3945/ajcn.2008.26847

33. Heo M, Faith MS, Pietrobelli A, Heymsfield SB. Percentage of body fat cutoffs by sex, age, and race-ethnicity in the US adult population from NHANES 1999-2004. *Am J Clin Nutr.* Published online 2012. doi:10.3945/ajcn.111.025171

34. Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of sarcopenia. *J Nutr Heal Aging.* Published online 2008. doi:10.1007/BF02982703

35. Zoico E, Di Francesco V, Guralnik JM, et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. *Int J Obes.* Published online 2004. doi:10.1038/sj.ijo.0802552

36. Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. *J Appl Physiol.* Published online 2007. doi:10.1152/japplphysiol.00627.2006

37. Kim TN, Yang SJ, Yoo HJ, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean sarcopenic obesity study. *Int J Obes.* Published online 2009. doi:10.1038/ijo.2009.130

38. Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: Prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). *Diabetes Care.* Published online 2010. doi:10.2337/dc10-0107

39. Levine ME, Crimmins EM. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. *Obesity.* Published online 2012. doi:10.1038/oby.2012.20

40. Kim YS, Lee Y, Chung YS, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the fourth Korean National Health and Nutritional Examination Surveys. *Journals Gerontol - Ser A Biol Sci Med Sci.* Published online 2012. doi:10.1093/gerona/gls071

41. Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. *J Cachexia Sarcopenia Muscle.* Published online 2016. doi:10.1002/jcsm.12076

42. Chang CI, Huang KC, Chan DC, et al. The impacts of sarcopenia and obesity on physical performance in the elderly. *Obes Res Clin Pract.* Published online 2015. doi:10.1016/j.orcp.2014.08.003

43. Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC. Sarcopenic obesity is closely associated with metabolic syndrome. *Obes Res Clin Pract.* Published online 2013. doi:10.1016/j.orcp.2012.02.003

44. Kohara K. Sarcopenic obesity in aging population: Current status and future directions for research. *Endocrine.* Published online 2014. doi:10.1007/s12020-013-9992-0

45. Kemmler W, von Stengel S, Engelke K, Sieber C, Freiberger E. Prevalence of sarcopenic obesity in Germany using established definitions: Baseline data of the FORMOsA study. *Osteoporos Int.* Published online 2016. doi:10.1007/s00198-015-3303-y

46. Y. R, V. L-C, C. C, et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSSteoporose) Study. *Am J Clin Nutr.* Published online 2009.

47. Ryu M, Jo J, Lee Y, Chung YS, Kim KM, Baek WC. Association of physical activity with
sarcopenia and sarcopenic obesity in community-dwelling older adults: The fourth Korea National Health and Nutrition Examination Survey. *Age Ageing*. Published online 2013. doi:10.1093/ageing/aft063

48. Batsis JA, Barre LK, Mackenzie TA, Pratt SI, Lopez-Jimenez F, Bartels SJ. Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: Dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. Published online 2013. doi:10.1111/jgs.12260

49. de Campos GC, Lourenço RA, Lopes CS. Prevalence of Sarcopenic Obesity and its Association with Functionality, Lifestyle, Biomarkers and Morbidities in Older Adults: the FIBRA-RJ Study of Frailty in Older Brazilian Adults. *Clinics (Sao Paulo)*. 2020;75(18):e1814. doi:10.6061/clinics/2020/e1814

50. Gallagher D, Belmonte D, Deurenberg P, et al. Organ-tissue mass measurement allows modeling of ree and metabolically active tissue mass. *Am J Physiol - Endocrinol Metab*. Published online 1998. doi:10.1152/ajpendo.1998.275.2.e249

51. Wilson MMG, Morley JE. Invited review: Aging and energy balance. *J Appl Physiol*. Published online 2003. doi:10.1152/japplphysiol.00313.2003

52. Conley KE, Esselman PC, Jubrias SA, et al. Ageing, muscle properties and maximal O2 uptake rate in humans. *J Physiol*. Published online 2000. doi:10.1111/j.1469-7793.2000.00211.x

53. Conley KE, Jubrias SA, Esselman PC. Oxidative capacity and ageing in human muscle. *J Physiol*. Published online 2000. doi:10.1111/j.1469-7793.2000.t01-1-00203.x

54. Sowers MF, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: Ovarian and chronological aging. *J Clin Endocrinol Metab*. Published online 2007. doi:10.1210/jc.2006-1393

55. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. *Br J Pharmacol*. Published online 2008. doi:10.1038/bjp.2008.118

56. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? *Int J Impot Res*. Published online 2009. doi:10.1038/ijir.2008.60

57. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. *Nat Rev Endocrinol*. Published online 2018. doi:10.1038/s41574-018-0062-9

58. Sharma D, Hawkins M, Abramowitz MK. Association of sarcopenia with egfr and misclassification of obesity in adults with ckd in the United States. *Clin J Am Soc Nephrol*. Published online 2014. doi:10.2215/CJN.02140214

59. Tovo C V., Fernandes SA, Buss C, De Mattos AA. Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review. *World J Hepatol*. Published online 2017. doi:10.4254/wjh.v9.i6.326

60. Merli M, Lattanzi B, Aprile F. Sarcopenic obesity in fatty liver. *Curr Opin Clin Nutr Metab Care*. Published online 2019. doi:10.1097/MCO.0000000000000558

61. Lee Y, Doumouras AG, Yu J, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. Published online 2019. doi:10.1016/j.cgh.2018.10.017

62. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. Published
63. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. *World J Gastroenterol*. Published online 2011. doi:10.3748/wjg.v17.i23.2801

64. Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in liver cirrhosis. *Int J Mol Sci*. Published online 2017. doi:10.3390/ijms18071392

65. Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. *Int J Cancer*. Published online 2013. doi:10.1002/ijc.28105

66. Henningsen J, Rigbolt KTG, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. *Mol Cell Proteomics*. Published online 2010. doi:10.1074/mcp.M110.002113

67. Bonala S, McFarlane C, Ang J, et al. Pid1 induces insulin resistance in both human and mouse skeletal muscle during obesity. *Mol Endocrinol*. Published online 2013. doi:10.1210/me.2013-1048

68. Zhang C, McFarlane C, Lokireddy S, et al. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. *Diabetologia*. Published online 2011. doi:10.1007/s00125-011-2079-7

69. Park SH, Park JH, Song PS, et al. Sarcopenic obesity as an independent risk factor of hypertension. *J Am Soc Hypertens*. Published online 2013. doi:10.1016/j.jsh.2013.06.002

70. Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. *N Engl J Med*. Published online 2017. doi:10.1056/nejmra1503519

71. Pan X, Han Y, Zou T, et al. Sarcopenia contributes to the progression of nonalcoholic fatty liver disease-related fibrosis: A meta-analysis. *Dig Dis*. Published online 2018. doi:10.1159/000491015

72. Carneiro IP, Mazurak VC, Prado CM. Clinical Implications of Sarcopenic Obesity in Cancer. *Curr Oncol Rep*. Published online 2016. doi:10.1007/s11912-016-0546-5